GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bliss GVS Pharma Ltd (BOM:506197) » Definitions » Research & Development

Bliss GVS Pharma (BOM:506197) Research & Development : ₹0 Mil (TTM As of Mar. 2025)


View and export this data going back to 1991. Start your Free Trial

What is Bliss GVS Pharma Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Bliss GVS Pharma's Research & Development for the three months ended in Mar. 2025 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was ₹0 Mil.

Bliss GVS Pharma Research & Development Historical Data

The historical data trend for Bliss GVS Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bliss GVS Pharma Research & Development Chart

Bliss GVS Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 104.01 220.04 217.89 337.25 -

Bliss GVS Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bliss GVS Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bliss GVS Pharma  (BOM:506197) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bliss GVS Pharma Research & Development Related Terms

Thank you for viewing the detailed overview of Bliss GVS Pharma's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Bliss GVS Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bliss GVS Pharma Ltd (BOM:506197) » Definitions » Research & Development
Comparable Companies
BOM:530199 BOM:531633 BOM:524470 BOM:507789 BOM:540737 BOM:543389 BOM:524669 BOM:506260 BOM:524212 BOM:506414 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
BLISSGVS:India
Address
Saki Vihar Road, 102, Hyde Park, Andheri (East), Mumbai, MH, IND, 400072
Website
https://www.blissgvs.com
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from exports.

Bliss GVS Pharma Headlines

No Headlines